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RTKs have been reported to be implicated in several neurodegenerative disor-
ders and the roles of insulin receptor family have emerged as a key common path-
way across diseases. Thus we focussed on the Insulin receptor family and discussed 
the irregulation from the growth hormone axis. The signaling, regulation and 
physiology of the production in liver and CNS has never been discussed in signaling 
perspectives and is extremely crucial for understanding the possibilities of IGF1 in 
neurodegeneration specifically. The commonalities across neurodegenerative dis-
eases such as oxidative stress, mitochondrial dysfunction, and protein misfolding 
and insulin pathway anomalies have been elucidated and correlated with the insulin 
pathway. The crosstalk possibilities of the pathways, along with other regulatory 
modes for the development of combinatorial therapy have been discussed to visual-
ize a common platform for neurodegenerative diseases including AD, PD, HD, ALS 
and FTD. Furthermore, the incretin based therapies that have gradually emerged as 
alternatives for insulin based therapy due to its inherent drawback of resistance has 
been briefly discussed.
Keywords: neurodegeneration, insulin, IGF1, GPCR, combinatorial therapy, 
lncRNA, Alzheimer’s disease
1. Introduction
Insulin dysregulation is a common phenomenon in several diseases, though 
their cause-effect relationship with progression is debatable. This review focuses 
on the degenerative pathways but essentially incorporates cues from prolifera-
tive mechanisms to develop a holistic approach towards understanding the 
disease progression. In case of neurodegeneration such as that in Alzheimer’s 
disease [AD], Huntington disease [HD], Fronto temporal Dementia [FTD] and 
Parkinson’s disease [PD], insulin dysregulation has been reported [1]. Therapies 
have been successfully developed encompassing the insulin pathway in ADwhere 
intranasal administration of insulin assists in recuperation, however resistance 
towards insulin and mode of administration remains an elusive matter [2]. Similar 
strategies are gradually being developed for FTD as well using Novolin-R insulin 
[3]. Insulin shock therapy for the schizophrenic patients was one of the initial 
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approaches towards tackling the disease, but with time insulin resistance or insen-
sitivity to higher dosages led to search for better ways of ameliorating the disease 
on relapse [4]. Insulin like growth factor 1 [IGF1] therapy has been implemented 
in ADbut due to the lack of conclusive evidence, resistance and contentious results 
from experimental models, the attempt did not stand the test of time [5]. It is thus 
impending to further investigate the modes of regulation and pathways which 
could lead the therapeutic development.
Insulin receptor family is a subset of the broader Receptor Tyrosine kinase 
[RTK] family comprised of 20 precise receptor sub-families further sub divided 
into more families based on ligand and domains of the receptors that play varied 
roles in neurodegeneration [6]. They include ErbB, PDGF, Ins, VEGF, FGF, Trk, 
PTK7, Ror, MuSK, Met, Axl, Tie, Eph, Ret, Ryk, DDR, ROS, LMR, STYK1 and ALK 
[7]. Many of these families have been shown to be involved in AD, PD as well as 
proliferative diseases such as cancer. The alterations in expression as well as activity 
has been documented which clearly elucidates the importance of understanding 
the roles of these receptors in disease pathology. With respect to neurodegeneration 
however, the roles played by RTKs are gradually being explored and understood 
since the complexities both on the membrane front and intracellular pathways are 
numerous. Insulin receptor family composed of Insulin Receptor [INSR], Insulin 
like growth factor receptor [IGF1R, IGF2R], and Insulin receptor related recep-
tor [INSRR] [8] forms a common bridge for understanding neurodegenerative 
pathways as they are implicated in almost all diseases and relatively well studied yet 
poorly understood. It is crucial to mention that unlike other members of the insulin 
family, INSRR is an orphan receptor with no known ligand. Recent studies have 
shown that it is pH sensitive and the receptor is activated by alkaline pH [9].IGF2R 
unlike IGF1R is non-mitogenic and involved in targeting IGF2 to lysosomes for 
degradation. It basically functions in signal attenuation and on overexpression has 
been reported to increase the amyloid beta generation [10].
Thus we begin with an overview of the hallmarks of neurodegeneration, their 
underlying mechanisms in brief and then delve into the possibility of therapeutics 
encompassing insulin pathway as a future prospect for palliation of neurodegenera-
tion. Insulin pathway involves mainly insulin andIGF1 which elicit different roles 
in the cell despite being structurally similar with common pathways that had been 
studied for decades but is still poorly understood in the context of neurodegenera-
tion. Insulin pathway being a metabolic pathway primarily, is capable of modulat-
ing several downstream important signaling molecules and influences metabolism, 
growth and survival through P13K pathway and MAPK mediated pathway that 
determines cellular fate [11].IGF1 additionally engages in the Jak–stat pathway [12] 
and uses several components of the GPCR pathways and in turn get regulated by 
them as well [13].
2. Commonalities of neurodegenerative diseases
Neurodegenerative diseases like Alzheimer’s and Parkinson have been long 
studied and the key proteins identified have been tried and tested for targeting in 
order to ameliorate the disease. However most of it has failed [14]. Several muta-
tions have been identified for both such as APOEε4 allele, APP, PSEN1 and PSEN2 
for AD, but people without any of these mutations have also been found to develop 
the disease [15], which adds to the complexity. The triggers for both these diseases 
have been shown to be associated with multiple factors as diverse as gut microbiota 
for PD [16], bacterial infections of the gum for AD [17], or genetic pre disposition 
and epigenetic modifications.
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Patients with Huntington often develop diabetes, whereas those with diabetes are 
more prone to developing AD [18]. The impairment of insulin pathways is common 
across patients suffering from different neurodegenerative diseases. Studies with 
transfected striatal nerve cells in vitro, showed that IGF1 can block the mutant 
protein huntingtin-induced cellular death and decreases formation of intranuclear 
inclusions [19]. Reduction in apoptosis was perhaps not the reason for this observa-
tion since BDNF which does the same, did not prohibit formation of such inclusions. 
The mitochondrial dysfunction in these striatal cell lines derived from huntingtin 
Knock-in mice is perhaps ameliorated by insulin and IGF1. The roles of these factors 
have further been observed in several studies where reduced energy metabolism in 
lymphoblasts derived from HD patients was shown to be associated with downregu-
lation of Akt and Erk activation which can be helped with IGF1 and insulin [20].
ALS and FTD are different diseases but both elicit a degeneration of neurons, 
their clinical as well as pathological manifestations are similar. Interestingly both 
of these display alterations in Growth hormone and IGF1 secretions [21]. ALS was 
initially characterized by the mutation in a gene, Superoxide dismutase [SOD1] 
with a 10–20% incidence in patients and since then more than a hundred different 
types of SOD1 mutations that cause ALS has been discovered [22]. The trigger for 
ALS and proposed mechanism though could be through growth hormones anomaly, 
could as well be through glutamate-induced neurotoxicity with an aberrant increase 
in glutamate concentration in CSF [23].
The aggregated proteins form intra cellular inclusions or extra cellular aggre-
gates in different brain areas. These proteins usually have a beta -sheet structure 
that allows aggregation and fibril formation as part of the misfolding process [24]. 
Misfolding of protein aggregates is one of the key underlying cause of neurode-
generation. Amyloid fibrils form plaques found in AD, Phosphorylated tau leads to 
neurofibrillary tangles, prions mediate in neurodegeneration and alpha synuclein 
aggregates in PD are also common [25].
In case of PD, ALS and AD, upto10% cases are inherited. However, in HD almost 
every case has a familial history [26]. The common disease/common variant [CD/
CV] hypothesis explains that common disorders are governed by common DNA 
variants which elevates risks but are usually not causative factors and might add to 
the understanding of genetic involvement in phenotypic manifestation of disease 
[27]. For example, the Apolipoprotein E [APOE] encodes a 299 amino acid long 
glycoprotein and is estimated to be a major contributing factor in AD development. 
It has also been reported in PD [27]. This similarity further elicits that neurode-
generative disorders might have a common underlying protein–protein interaction 
network (Figure 1). Also, intervention for neurodegenerative disorders could be 
facilitated by exploring the genes and its regulatory components including ncRNAs 
that might govern the progression and allow scope of regulating the protein–pro-
tein network downstream [28, 29]. Studies have focused on individual disorders 
but rarely generated a common platform that allows better understanding of the 
network by taking varied disorders into perspective.
Amongst the hallmarks of neurodegeneration that significantly contributes 
towards the progression is oxidative stress. It has been implicated in several diseases, 
including AD, PD and ALS [30]. Extensive oxidation of lipids, DNA and proteins 
leads to deactivation of major processes or upregulation of toxic cellular cascades. 
The imbalance in the scales of Reactive oxygen species [ROS] generation damages the 
cells [31]. Amyloid beta which is originally generated by neurons in AD in response to 
insults and cellular damage in pursuit of protection, in turn coordinates iron and cop-
per to generate peroxide that accelerates ROS generation by Fenton chemistry [14]. 
Dopamine buildup in cytoplasm in PD coordinates iron and induces ROS formation. 
Active site destabilization of SOD also allows further oxidation. Such unregulated 
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ROS further affects calcium regulation which leads to excitotoxicity [32]. The current 
drugs encompassing ROS generation affect the rate of progression at late stages and 
thus it is increasingly important to understand the growth hormone axis that changes 
early in the disease cycle and determines the final outcome, ROS generation and toxic 
misfolding of proteins aggregates amongst other catastrophic events that lay ahead of 
the domino like cascade of neurodegenerative pathways.
3. Insulin resistance and neuroinflammation
The growth factors bind to receptors and they no longer respond to the ligand 
binding when resistance develops, which would have otherwise triggered a cascade 
of downstream signaling. Several studies have attempted to evaluate the total IGF1 
or Insulin levels that are responsible for the resistance to overcome it. Dosage up 
to 100 nM Insulin even instead of physiologically relevant 1 nM have been unsuc-
cessful in reinstating the sensitivity. This further drives attention towards the 
receptor [33]. The anomalies in the reports pertaining to the receptor stimulation 
Figure 1. 
Commonalities across neurodegenerative disorders, two or more are often shared.
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particularly in AD clearly elucidate a faulty signaling cascade operating at different 
stages of the disease [2]. The receptors of the Insulin family, vis-à-vis INSR and 
IGF1R are elusive and bind to both ligands, Insulin and IGFs. Their diverse intracel-
lular domains allows them to bind several other adaptor proteins other than the 
conventional mediators of signaling cascade, IRS1 and IRS2 [34]. There are numer-
ous astounding facts about these receptors which make them unique targets and add 
to their therapeutic value. INSR and IGF1R forms hybrids that has a higher affinity 
for IGF1 [35–37] but their activity if its varied from individual dimers and their 
respective localization after stimulation is unknown. The insulin resistance poses a 
major setback to its therapeutic value and correcting the axis by identifying other 
players in the cascade both downstream and at the membrane front could thus help 
in re-sensitizing the receptors.
Both Insulin and IGF1R has been shown to enter the nucleus when activated 
recently and it is speculated that they perform physiological roles which might be 
altered in different disease situations [38]. It has been experimentally illustrated as 
an orchestrated event that occurs physiologically in non-cancerous cell lines along 
with different cancers, in which this behavior of nuclear migration was first found. 
It however remains due to illustrate the proportions of the nuclear and cytoplasmic 
amount of IGF1R in different disease conditions where these metabolic signaling 
pathways are known to be altered. Their phosphorylation status too remains to be 
explored since IGF1R has multiple phosphorylation sites [39] and they could be 
important in understanding their role in neurodegeneration.
Recent studies show that phosphoINSR can be translocated into the nucleus in 
a clathrin mediated manner. It forms a complex with RNA pol-II, HCF 1 and DNA 
binding transcription factors like THAP 11. Mass-spectrometry data shows the 
translocation involves KPNA 2 and HSP 70 [40].
IGF-1R has been observed in the nucleus in case of prostate cancer and breast 
cancer cells. Full length IGF-1R alpha and beta chains were reported in the nuclear 
extract of prostate cancer cells. This is the only example of a receptor which traffics 
as individual sub unit to the nucleus [41]. Other RTKs such EGFR, FGFR has also 
been previously been observed in the nucleus. The endocytosis is here both clathrin 
and caveolin mediated. The nuclear transport here is not mediated by adaptor 
proteins like IRS 1 or an inherent NLS but by SUMOylation [42].
The cause and effect relationship for the ever so complex pathway and its 
involvement in AD or PD remains unclear and further experimental studies are 
required to investigate the connection of this underlying nuclear migration with 
disease progression. The ligands and receptors need to betreated an individual 
elements instead of a holistic component in the cascade, since there remains the 
possibility that Insulin and IGF1 both can stimulate other receptors [43]. The con-
cerned receptors could be activated in diseases like AD by Amyloid beta fragments 
[44, 45] and behave differently in terms of interacting partners and localization, 
thus altering the signaling cascade majorly.
4.  Insulin as a growth factor with prospects in therapeutics for 
neurodegeneration
Insulin production in the body was assumed to primarily happen in the pancreas 
and circulated throughout, however production in the CNS of both insulin and IGF1 
is now proven [46–48]. Insulin production in CNS appears to be important for the 
lower organisms than that in higher organism like humans. However further research 
in the last decade has yielded results that clearly indicate that insulin is secreted in 
the CNS and might play important roles in physiology. The amount of the same is 
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presumed to be lower compared to the pancreas derived insulin which is transported 
into the brain through receptor mediated transcytosis. However it can also be inde-
pendent of the receptor as illustrated by [49]. Insulin circulating in the bloodstream 
binds to receptors present on the endothelial cells at the blood brain barrier which is 
further moved into the interstitial fluid. There it binds to insulin receptors distributed 
throughout the cerebral cortex, olfactory bulb, hippocampus, hypothalamus, amyg-
dala and septum [48]. IGF1 on the other hand, binds to one of its 6 binding proteins 
and remains in the inactive form in the bloodstream and in local tissues. The entrance 
into the brain occurs in a similar fashion as in the case of insulin [50].
Several parts of the brain are sensitive towards insulin and they have a different 
relationship associated with the alterations of the levels. Neuroimaging studies have 
shed light on the insulin induced brain responses in the fusiform gyrus, hippocampus, 
pre-frontal cortex, striatum, hypothalamus and insular cortex. Thus healthy insulin 
signaling controls brain networks implicated in reward processing, memory retrieval, 
homeostatic control and cognitive control in general [51]. These wide involvements of 
insulin in regulation of distinct parts of the brain responsible for different activities 
leads to the marked impact of a mild dysregulation and thus indicate an alteration 
could infact be an initial event in the cascade of neurodegeneration.
Insulin is known to activate cell growth, cell repair, mitochondrial activity, gene 
expression, energy utilization and protein synthesis for decades. In both AD and 
PD, insulin signaling pathway and downstream regulators contribute significantly 
to the pathology of the disease. Insulin signaling in the brain of these patients is 
desensitized and while analyzing post-mortem brains, it appears that they have 
inactivated receptors and downstream IRS1 and 2 as well. The key secondary mes-
sengers of this signaling pathway, Akt and mTOR also appears to be inactivated in 
these patients as it is observed diabetes [14, 20, 27]. Thus, AD was termed as Type 
3 diabetes where a systemic resistance to the pathway occurs [52]. However, unlike 
diabetes the reasons could be very different. Insulin desensitization occurring in the 
brain could be part and parcel of the inflammatory response in the brain. In case of 
AD, where amyloid beta aggregates lead to plaque formation, the oxidative stress 
and cytokines involvement in the long run could restrict the supply of the insulin 
and IGF essential for growth and repair of the neurons [53]. Pro-inflammatory 
cytokines like Tumor necrosis factor [TNF] could possibly block the signaling 
pathways of insulin and IGF1.
Saenger et al. [54] investigated into the SOD1-G93A mouse lines that elicit ALS 
like pathology, both mild and severe phenotype form. The results indicated IGF1 
therapy in the early stages can be effective but in case of severe cases, the functional 
outcomes were no better. Despite increase signaling in brain, at high doses, survival 
chances did not improve. Clinical trials that evaluated the role of Growth hormones 
in patients with ALS yielded mixed results. Researchers back in 1993 employed a very 
small dosage [0.1 mg/day] which impacted the IGF1 levels after therapy. In another 
study recently in 2012, 2.8 mg/day was used, but that further led to a reduction in the 
IGF1 and IGF1-BP3 demonstrating the effectiveness of the therapy further [46].
5. IGF1 as a pleiotropic factor in aging and neurodegeneration
The brain receives its IGF1 supply through both autocrine and paracrine path-
ways. IGF1 is secreted by liver, in response to binding of growth hormone [GH] to 
their respective GH receptors, which leads to increase in the circulating IGF1 levels. 
The IGF1 thus secreted by liver then binds to their receptors IGF1R in the pituitary 
and hypothalamus, which in turn inhibits Growth hormone releasing hormone 
[GHRH] and Growth hormone [GH] production [46].
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The hepatic IGF1 production makes up for 70% of the total circulating ligand 
pool and caters to the brain by passing through the blood brain barrier at choroid 
plexus directly into the Cerebrospinal fluid [CSF] with the assistance of IGF1R 
and Megalin, a low density lipoprotein receptor related protein 2 transporter [46]. 
There is a clear feedback loop for the hepatic production regulation, but not for the 
autocrine production in the brain (Figure 2). Studies show mutations that manifest 
in GH deficiency or resistance present normal cognitive functionality [55] however 
when IGF1 production is globally eradicated or insensitivity is induced, that leads 
to microcephaly and cognitive deficits in children [56]. This suggests the autocrine 
brain production might be preserved in GH mutated scenarios and a separate feed-
back loop exists for that regulation. Adding to the complexity, the circulated IGF1 is 
bound to IGF binding proteins [IGFBPs] mainly IGFBP-3 being the most abundant, 
making them unavailable for receptor stimulation [57].
The autocrine production though expected to be independent of the hepatic IGF1 
production, appears to decline with age similarly. The endocrine decline in IGF1 levels 
has been related to the diminished GH pulse frequency and amplitude, observed in 
case of aging. It is partly due to the decrease in ghrelin binding to GH secretagogue 
receptor [GHSR] [57]. Aging and lowering of cognitive abilities is observed to be 
associated with lower levels of IGF1, where the receptor levels increase to compensate 
Figure 2. 
Feedback loop for hepatic and autocrine production of IGF1 in the brain.
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for the lower availability perhaps. The increase in the receptor levels in aged indi-
viduals could also be a coping mechanism for combating insults and stress induced 
due to the breach in blood brain barrier. Nevertheless, it is evident that IGF1 plays a 
major neutrophic role within PNS and CNS and is strongly involved in neurogenesis, 
anti-apoptotic, synaptogenesis and anti-inflammatory effects at cortical, sensory and 
motor levels and hence further investigation into the puzzling characteristics of the 
receptor shall shed light on the definitive involvement in neurodegeneration.
IGF1 other than being implicated in AD and other neurodegenerative diseases is 
also a major risk factor for cancer. Its upregulation is a major implication of prolif-
eration in several cancers. Modulation of the cell cycle, apoptosis and cell survival 
through interaction with IRS1 and IRS2 and downstream effectors like PI3K/AKT/
mTOR allows IGF1 to drive the cell towards proliferation [58]. Some pre-clinical 
studies state that mutations in genes that control the GF/INS/IGF axis can increase 
the lifespan even in invertebrate and vertebrate animal models [59].
Aging and IGF1 are intertwined on several levels, adding to the complexity of 
the insulin pathway. Research shows IGF1 deficiency could slower aging [60–63] 
and thus is a separate concern for therapy development for patients who develop 
Late onset AD [LOAD]. However combinatorial treatment with other membrane 
receptor antagonists or agonists for that matter which are implicated in the diseases 
could offer better options for prophylaxis.
6. Impact of growth factors on the neurophysiology
The amyloid hypothesis that focuses primarily on the protein misfolding that 
occurs in AD and aggregation associated with it largely fails at analyzing the actual 
neuronal pathophysiological developments in the brain. Inflammatory mediators 
like cytokines can promote the state in CNS through several mechanisms, crossing 
the BBB or entering by circumventricular organs, communication transmitted via 
the vagal nerve, and signaling through the cerebral endothelium [51]. These path-
ways allow insinuation and perpetuation of pro-inflammatory responses within the 
brain. Amyloid beta oligomerisation and tau phosphorylation which are hallmarks 
of AD can also be promoted through such changes [51].
The impact of growth factors comes into play since important cellular phenomena 
like inflammation and underlying reasons for neuronal loss are in turn corrected with 
insulin based therapies. The problems with such therapies persist, and have been 
long known, as progressive resistance. Key growth factors present in the brain such as 
BDNF, NGF, GDNF, IGF1 and insulin all lose their capacity of reversing or controlling 
the damage over time [64]. However, the improvements are often long lasting and dis-
ease progression is halted effectively by them through receptors in the glia initially [51]. 
Neurodegenerationis a complex process andfactors like GLP1, GIP1, and insulin cross 
the blood brain barrier in order to provide protection on several levels including ROS 
generation. In response to these, synaptic activity as well as plasticity is restored, brain 
functionality and memory retention is improved, and mitogenesis and mitochondrial 
function which dysregulates the energy utilization is also corrected [65]. Autophagy 
occurs normally and apoptosis rates are reduced as well.
7.  Future prospects: cross talk between insulin signaling and other 
pathways
In order to improve the capabilities of the insulin therapy and circumvent 
the issues with hyperinsulinemia, it is important to understand the crosstalk 
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possibilities for this important axis. The goal to re-sensitize the cells towards treat-
ment or induce a similar cascade by receptor stimulation through other ligands or 
adaptors could pave the way for combinatorial therapy. Thus, understanding the 
cross talk possibilities for neurodegenerationis impending. In case of heart diseases 
a crosstalk between insulin receptors and beta 2 adrenergic receptors [β2AR] is 
found which paved the path towards understanding the exploitation of GPCR 
signaling pathways by RTKs [66]. RTKs can use Beta arrestin, G protein receptor 
kinases, insulin to directly induce tissue RAS activation, regulate beta-adrenergic 
catecholamine stimulation and even to attenuate contractile response to β2AR 
stimulation in myocardial ischemia [67].
Angiotensin II [AII] acts on the cell by virtue of its receptor and since 1996, 
the direct connection between the two pathways on the phosphorylation and the 
downstream P13K activity has been known. Stimulation with AII inhibited both 
basal and insulin stimulated PI3K activity in rats [68].
Amongst interesting findings, IGF1R has been found to exist in associa-
tion with GABAB, which offers neuroprotection to cerebellar granule neurons 
from low potassium induced apoptosis. This process involves Akt recruitment 
and activation of IGF1R with the assistance of Gi/o- protein and FAK1 [69, 70]. 
Antidepressants can potentially trans-activate RTKs like EGFR by inducing 
activation of LPA receptors [71]. Reports show that acute MOR agonists can 
induce beta arrestin dependent and src-dependent IGF1R transactivation through 
subsequent Erk phosphorylation, prolonged treatment with the agonist however 
leads to heterologous desensitization of IGF1R based cascade [72]. The studies 
corroboratively indicate insulin GPCR heterocomplex plays important roles in 
different tissues and several of such associations could be involved in neurons in 
physiological and disease scenarios as well.
Studies show IGF1 receptor signaling and anti-apoptotic activity in cortical 
neurons is partly due to the Src dependent PACAP type I receptor which is trans-
activated [73]. Non-canonical insulin pathway receptors like TrkA has also been 
observed in such complexes with another receptor LPA1 that allows for constitutive 
activation of the cascade involving ERK1/2 in response to NGF [71]. IGF1 can also 
mediate G protein dependent ERK1/2 activation through transactivation of sphin-
gosine 1 phosphate receptors [73].
Dopamine and Insulin signaling pathways are also intertwined as they elicit 
a reciprocal relationship. Antagonism of D2 receptors for a short duration leads 
to upregulation of insulin secretion [74]. Insulin can also enhance reuptake of 
dopamine, which has been visualized with respect to mental health and metabolic 
syndromes.
Recent studies on ncRNAs are also evolving and shows that several lnc RNAs 
and miRs that are involved in controlling key phenomena in neurodegenerative 
diseases like AD, PD, HD and ALS. Long non-coding RNAs like BACE1-AS, 
XIST are upregulated in AD [75, 76]. Neat1 and MALAT1 are upregulated 
in FTD as well as ALS, where they form paraspeckles with TDP-43 and FUS 
proteins. UCHL1-AS1 leads to perturbation of ubiquitin-proteasome system 
that and is upregulated in PD. HTT-AS, HAR1 and BDNF-AS were reported 
to be dysregulated in HD. Interestingly, insulin responsiveness of these genes 
have not been explored in neuronal perspective. Some lncRNAs such as H19, 
lncASIR have been reported by several groups [29, 77] but their implications 
and involvement, interaction with other proteins or ncRNAs shall open up 
avenues for therapy oriented research. Furthermore, Lnc RNAs that are known 
to interact with these receptors such as IRAIN, GAS5, NNT-AS1 [78] needs to 




8.  Combinatorial & peptide based therapies: insulins, incretins and 
drugs
Insulin resistance remains a major challenge towards drug development and 
meanwhile alternative strategies encompassing hormones are being tested and devel-
oped forneurodegenerative diseases. Incretin hormones like GLP1 and GIP show 
similar therapeutic roles and do not lead to insulin desensitization, as they do not 
activate the receptors however they lend similar effects [79]. Furthermore, analogues 
of the peptide hormones do not affect the blood glucose levels in non-diabetics with 
normoglycemic index. The side effects are mild loss of appetite and nausea. Detemir 
study led to this important realization that drugs for non-diabetic with AD or PD 
who require intervention with hormones needs to be developed with caution. Those 
with higher peripheral insulin resistance performed better with the drug, however 
those with lower peripheral resistance suffered from worsening of memory forma-
tion. Though there is plenty to understand and explore about the insulin pathway 
and its role in complex multifactorial neurodegenerative diseases, the treatments 
encompassing these factors that appears to be effective must be discussed.
GLP1 is part of a peptide based growth factor family that activates a glucagon 
type GPCR, expressed in primates, rodents and human neurons. Other receptor 
agonists such as lixisenatidemliraglutide and semaglutide available for treating Type 
II diabetes are also being tested for eeffectiveness in AD and PD [1]. Some of them 
can traverse the blood brain barriers and are thus prospective game changers for 
therapeutics. GLP 1 mimetic have shown promising results in animal models of AD, 
they exhibit fascinating reduction of chronic inflammation which is a major driver 
for progression of disease.
GIP is another sister incretin that bind to a GPCR on the membrane and its 
receptor is abundant in a wide range of cells including pyramidal neurons, Purkinje 
cells in cerebellum and basal brain areas. It was capable of offering neuroprotection 
to APP/PS1 mice, reduced loss of synapses and recreated synaptic plasticity [79]. 
Furthermore, the amyloid plaque load was also reduced along with oxidative stress 
and DNA damage.
9. Conclusions
Substantial advancement in the field of growth hormone, RTKs and their 
involvement in neurodegeneration has been made in the last two decades. The 
development of peptide based therapies involving incretins that can mitigate the 
degenerative processes in the brain is a major feat that shows promise. Controlling 
this major InsR and IGF1R, which are prominent and one of the most important 
albeit in age reversal [61, 80] is yet to be achieved but picking up cues from diseases 
like cancer that elicits an alternate pathway [81], in terms of therapy could acceler-
ate the process of developing therapies (Figure 3). The ability of growth factors 
to modulate cellular events such as ROS generation, energy utilization and others 
are remarkable and thus developing more sophisticated approaches using the 
knowledge thus gathered to invoke the right set of signals for slowing the cycle and 
early detection are important. Though possibilities involving the insulin pathway 
have been only explored on the protein level, regulation on the RNA level could be 
utilized yet to enhance sensitivity.
Pre-clinical studies from growth hormone therapies often leave out important 
aspects like multiple binding partners, transactivation and cross talks that leads to 
different results when applied to humans. Research on analogues with no resistance, 
compounds that re-instate sensitivity and alternative drugs such as mAbs against 
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RTKs altered are the need for the hour. The current peptide based drugs on the market 
are promising since they can potentially reverse a range of pathophysiological param-
eters of neurodegeneration. However understanding the hormonal axis that led to 
the death is important for further biomarker development and therapy development 
as well. The growth hormone axis could indeed be an underlying cause amongst the 
plethora of factors already known for neurodegeneration. Studies on their involve-
ment in determining cellular fate and their tuning in accordance with progression 
of disease are required for developing a better understanding about stages of the 
progressive disorders discussed holistically. The crosstalk with other pathways and 
gradual involvement of several miR and Lnc RNA which are crucial are complicating 
the story and yet simplifying it in terms of the puzzling and contentious results.
In conclusion, it is apparent that the neurodegenerative disorders have an under-
lying insulin pathway abnormality and growth hormone axis plays a major role the 
CNS and in turn affects progression of neurodegeneration. The Insulin receptor 
family amongst the RTKs is an important set that could lead the path towards 
therapies for degenerative disorders in a non-invasive manner if understood in their 
entirety and the regulation though complex could be a common network of pro-
tein–protein interaction that would simplify prognosis and prophylaxis.
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